Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{20a63031dfd945ad813b117ce9464658,
title = "Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction",
abstract = "Background: Identification of patients at high risk of non-cardiac mortality following ST-segment elevation myocardial infarction (STEMI) could guide clinicians to identify patients who require attention due to serious non-cardiac conditions after the acute phase of STEMI. The purpose of this study was to evaluate if the non-specific and prognostic biomarker of inflammation and comorbidity, soluble urokinase receptor (suPAR), could predict non-cardiac mortality in a cohort of STEMI patients. Methods: SuPAR was measured in 1,190 STEMI patients who underwent primary percutaneous coronary intervention (pPCI). The primary endpoint was non-cardiac mortality, secondary endpoints were cardiac mortality, all-cause mortality, reinfarction and periprocedural acute kidney injury. Backwards elimination of potential confounders significantly associated with the respective outcome was used to adjust associations. Results: Patients were followed for a median of 3.0 years (interquartile range 2.5– 3.6 years). Multivariate cox regression revealed that a plasma suPAR level above 3.70 ng mL −1 was associated with non-cardiac and cardiac mortality at hazard ratios 3.33 (95{\%} confidence interval 1.67–6.63, p = 0.001, adjusted for age) and 0.99 (0.18–5.30, p = 0.98, adjusted for previous myocardial infarction and left ventricular ejection fraction), respectively. Conclusion: In patients with pPCI treated STEMI, suPAR was an independent prognostic biomarker of non-cardiac but not cardiac mortality and may identify patients with high risk of non-cardiac mortality.",
keywords = "Acute coronary syndrome, Biomarker, Low-grade inflammation, suPAR",
author = "Andreas Sand{\o} and Martin Schultz and Jesper Eugen-Olsen and Lars K{\o}ber and Thomas Engstr{\o}m and Henning Kelb{\ae}k and Erik J{\o}rgensen and Kari Saunam{\"a}ki and Lene Holmvang and Frants Pedersen and Tilsted, {Hans Henrik} and Dan H{\o}fsten and Steffen Helqvist and Peter Clemmensen and Kasper Iversen",
note = "Copyright {\circledC} 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = "6",
doi = "10.1016/j.clinbiochem.2020.03.013",
language = "English",
volume = "80",
pages = "8--13",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc",

}

RIS

TY - JOUR

T1 - Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction

AU - Sandø, Andreas

AU - Schultz, Martin

AU - Eugen-Olsen, Jesper

AU - Køber, Lars

AU - Engstrøm, Thomas

AU - Kelbæk, Henning

AU - Jørgensen, Erik

AU - Saunamäki, Kari

AU - Holmvang, Lene

AU - Pedersen, Frants

AU - Tilsted, Hans Henrik

AU - Høfsten, Dan

AU - Helqvist, Steffen

AU - Clemmensen, Peter

AU - Iversen, Kasper

N1 - Copyright © 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

PY - 2020/6

Y1 - 2020/6

N2 - Background: Identification of patients at high risk of non-cardiac mortality following ST-segment elevation myocardial infarction (STEMI) could guide clinicians to identify patients who require attention due to serious non-cardiac conditions after the acute phase of STEMI. The purpose of this study was to evaluate if the non-specific and prognostic biomarker of inflammation and comorbidity, soluble urokinase receptor (suPAR), could predict non-cardiac mortality in a cohort of STEMI patients. Methods: SuPAR was measured in 1,190 STEMI patients who underwent primary percutaneous coronary intervention (pPCI). The primary endpoint was non-cardiac mortality, secondary endpoints were cardiac mortality, all-cause mortality, reinfarction and periprocedural acute kidney injury. Backwards elimination of potential confounders significantly associated with the respective outcome was used to adjust associations. Results: Patients were followed for a median of 3.0 years (interquartile range 2.5– 3.6 years). Multivariate cox regression revealed that a plasma suPAR level above 3.70 ng mL −1 was associated with non-cardiac and cardiac mortality at hazard ratios 3.33 (95% confidence interval 1.67–6.63, p = 0.001, adjusted for age) and 0.99 (0.18–5.30, p = 0.98, adjusted for previous myocardial infarction and left ventricular ejection fraction), respectively. Conclusion: In patients with pPCI treated STEMI, suPAR was an independent prognostic biomarker of non-cardiac but not cardiac mortality and may identify patients with high risk of non-cardiac mortality.

AB - Background: Identification of patients at high risk of non-cardiac mortality following ST-segment elevation myocardial infarction (STEMI) could guide clinicians to identify patients who require attention due to serious non-cardiac conditions after the acute phase of STEMI. The purpose of this study was to evaluate if the non-specific and prognostic biomarker of inflammation and comorbidity, soluble urokinase receptor (suPAR), could predict non-cardiac mortality in a cohort of STEMI patients. Methods: SuPAR was measured in 1,190 STEMI patients who underwent primary percutaneous coronary intervention (pPCI). The primary endpoint was non-cardiac mortality, secondary endpoints were cardiac mortality, all-cause mortality, reinfarction and periprocedural acute kidney injury. Backwards elimination of potential confounders significantly associated with the respective outcome was used to adjust associations. Results: Patients were followed for a median of 3.0 years (interquartile range 2.5– 3.6 years). Multivariate cox regression revealed that a plasma suPAR level above 3.70 ng mL −1 was associated with non-cardiac and cardiac mortality at hazard ratios 3.33 (95% confidence interval 1.67–6.63, p = 0.001, adjusted for age) and 0.99 (0.18–5.30, p = 0.98, adjusted for previous myocardial infarction and left ventricular ejection fraction), respectively. Conclusion: In patients with pPCI treated STEMI, suPAR was an independent prognostic biomarker of non-cardiac but not cardiac mortality and may identify patients with high risk of non-cardiac mortality.

KW - Acute coronary syndrome

KW - Biomarker

KW - Low-grade inflammation

KW - suPAR

UR - http://www.scopus.com/inward/record.url?scp=85082548188&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2020.03.013

DO - 10.1016/j.clinbiochem.2020.03.013

M3 - Journal article

VL - 80

SP - 8

EP - 13

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -

ID: 59614964